trial · primary record
Sacituzumab tirumotecan
Bladder Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 590 |
| Primary completion | 2030-04-23 |
| Primary endpoint | Overall Survival (OS) |
| Registry ID | NCT07419295 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:36.699Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07419295
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Sacituzumab tirumotecan · compound